PureTech Health: Notice of Results

Rhea-AI Summary

PureTech Health plc announces its plans to release the annual report and financial results on April 28, 2023, at 2:00 AM EDT. This report will encompass financial data for the year ending December 31, 2022, along with the cash balance for Q1 2023. A presentation and conference call to discuss the results will occur at 9:00 AM EDT on the same day, with a webcast available on the company's website. Additionally, PureTech is set to provide updates on its Wholly Owned Pipeline and Founded Entities, including its commitment to environmental, social, and governance (ESG) practices. The company, known for its innovative biotherapeutics, has developed a pipeline comprising 26 candidates, with notable FDA-clear therapies like Plenity® and EndeavorRx®.

Positive

• Plans to release the annual report on April 28, 2023.
• Overview of business and strategy progress, including updates across the Wholly Owned Pipeline and Founded Entities.
• Pipeline consists of 26 therapeutic candidates with two already FDA-cleared.

Negative

• None.

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Friday, April 28, 2023, at 2:00 AM EDT/ 7:00 AM BST. The report will include the Company’s financial results for the year ended December 31, 2022, and its cash balance for the first quarter ended March 31, 2023. PureTech also plans to provide an overview of progress across its Wholly Owned Pipeline and Founded Entities in addition to the Company’s approach to environmental, social and governance (ESG) practices, along with other business and strategy progress and updates.

A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations.

About PureTech
PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 26 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that will soon be filed for FDA approval, as of the most recent update by the Company. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on its unique insights and technology platforms.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2021, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005780/en/

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com

EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

U.S. Media

Nichole Sarkis

+1 774 278 8273

nichole@tenbridgecommunications.com

Source: PureTech Health plc

FAQ

What date will PureTech Health publish its annual report?

PureTech Health will publish its annual report on April 28, 2023.

What financial year does the upcoming report cover?

The upcoming report covers the financial results for the year ended December 31, 2022.

What time will the conference call discussing the results take place?

The conference call will take place at 9:00 AM EDT on April 28, 2023.

How many therapeutic candidates does PureTech currently have?

PureTech currently has a pipeline consisting of 26 therapeutic candidates.

What are some of the notable therapies developed by PureTech?

Notable therapies developed by PureTech include Plenity® and EndeavorRx®, both of which have received FDA clearance.